[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100414666":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":27,"centralContacts":32,"locations":41,"responsibleParty":107,"collaborators":109,"id":117,"slug":118,"hasResults":119,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":123,"eligibilityCriteria":124,"healthyVolunteers":119,"sex":125,"minAge":126,"maxAge":10,"enrollmentInfo":127,"targetDuration":10,"studyType":130,"phases":10,"briefSummary":131,"conditions":132,"keywords":134,"overallStatus":68,"whyStopped":10,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":154},{"fullName":5,"class":6},"University Hospital Schleswig-Holstein","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Populationbased Platform (POP) of the National Pandemic Cohort Network (NAPKON)",null,"Streamlined sampling of biomaterials and core data elements (GErman Corona COnsensu data set, GECCO) with other NAPKON study platforms (HAP, SUEP).",[13],"Other: Observation of different courses of SARS-CoV-2 infection in different phases (acute vs. post-acute) and settings",{"label":15,"type":10,"description":16,"interventionNames":17},"High-Resolution Platform (HAP) of the National Pandemic Cohort Network (NAPKON)","Streamlined sampling of biomaterials and core data elements (GErman Corona COnsensu data set, GECCO) with other NAPKON study platforms (POP, SUEP).",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Intersectoral Platform (SUEP) of the National Pandemic Cohort Network (NAPKON)","Streamlined sampling of biomaterials and core data elements (GErman Corona COnsensu data set, GECCO) with other NAPKON study platforms (HAP, POP).",[13],[23],{"type":6,"name":24,"description":25,"armGroupLabels":26,"otherNames":10},"Observation of different courses of SARS-CoV-2 infection in different phases (acute vs. post-acute) and settings","Oberservatory Cohorts focusing (I) on subjects after SARS-CoV-2 infection that are recruited from the general population (POP), and on subjects with acute SARS-CoV-2 infections recruited (II) in university hospital high-care settings or (III) general health care",[15,19,9],[28],{"name":29,"affiliation":30,"role":31},"Stefan Schreiber, Prof. Dr.","Internal Medicine Department I, UKSH Kiel","STUDY_DIRECTOR",[33,37],{"name":29,"role":34,"phone":35,"phoneExt":10,"email":36},"CONTACT","0049 (0)431 500 22201","s.schreiber@mucosa.de",{"name":38,"role":34,"phone":39,"phoneExt":10,"email":40},"Thomas Bahmer, Prof. Dr.","0049 (0) 431 500 62629","thomas.bahmer@uksh.de",[42,66,90],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"University Hospital Wuerzburg","NOT_YET_RECRUITING","Würzburg","Bavaria","97080","Germany","DE",{"type":51,"coordinates":52},"Point",[53,54],9.95121,49.79391,{"lat":54,"lon":53},[57,61,63],{"name":58,"role":34,"phone":59,"phoneExt":10,"email":60},"Peter Heuschmann, Prof. Dr.","0931 201 470308","E_Heuschma_P@ukw.de",{"name":62,"role":34,"phone":59,"phoneExt":10,"email":10},"Jens-Peter Reese, Prof. Dr.",{"name":64,"role":65,"phone":10,"phoneExt":10,"email":10},"Stefan Stark, Prof. Dr.","SUB_INVESTIGATOR",{"facility":67,"status":68,"city":69,"state":70,"zip":71,"country":48,"countryCode":49,"cosmosGeoPoint":72,"geoPoint":76,"contacts":77},"University Hospital Schleswig-Holstein, Campus Kiel","RECRUITING","Kiel","Schleswig-Holstein","24105",{"type":51,"coordinates":73},[74,75],10.13489,54.32133,{"lat":75,"lon":74},[78,82,83,85,86,88],{"name":79,"role":34,"phone":80,"phoneExt":10,"email":81},"Anne Hermes, Prof. Dr.","0049 (0) 431 500 30240","info@covidom.de",{"name":38,"role":34,"phone":39,"phoneExt":10,"email":40},{"name":29,"role":84,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"name":38,"role":65,"phone":10,"phoneExt":10,"email":10},{"name":87,"role":65,"phone":10,"phoneExt":10,"email":10},"Lieb Wolfgang, Prof. Dr.",{"name":89,"role":65,"phone":10,"phoneExt":10,"email":10},"Krawczak Michael, Prof. Dr.",{"facility":91,"status":44,"city":92,"state":10,"zip":93,"country":48,"countryCode":49,"cosmosGeoPoint":94,"geoPoint":98,"contacts":99},"University Hospital Charité Berlin","Berlin","10117",{"type":51,"coordinates":95},[96,97],13.41053,52.52437,{"lat":97,"lon":96},[100,104],{"name":101,"role":34,"phone":102,"phoneExt":10,"email":103},"Thomas Keil, Prof. Dr.","0049 (0)30 450 529 902","thomas.keil@charite.de",{"name":105,"role":34,"phone":102,"phoneExt":10,"email":106},"Lilian Krist, Dr.","lilian.krist@charite.de",{"type":108,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[110,112,114],{"name":111,"class":6},"Charite University, Berlin, Germany",{"name":113,"class":6},"Wuerzburg University Hospital",{"name":115,"class":116},"German Federal Ministry of Education and Research","OTHER_GOV","100414666","covidom-longterm-morbidity-of-sars-cov-2-infection-and-covid-19-disease---consequences-for-health-status-and-quality-of-life-100414666",false,"NCT04679584","COVIDOM: Longterm Morbidity of SARS-CoV-2 Infection and COVID-19 Disease - Consequences for Health Status and Quality of Life","COVIDOM: Longterm Morbidity of SARS-CoV-2 Infection and COVID-19 Disease - Consequences for Health Status and Quality of Life (NAPKON-POP)","NAPKON-POP","Inclusion Criteria:\n\n* PCR-confirmed SARS-CoV-2 infection\n* living in one of the target areas\n* age at least 18 years\n* written informed consent\n\nExclusion Criteria:\n\n* Acute SARS-CoV-2 infection or reinfection","ALL","18 Years",{"count":128,"type":129},2000,"ESTIMATED","OBSERVATIONAL","COVID-19 is a novel disease caused by SARS-CoV-2 that primarily affects the lungs but also various other organs of the body already in early stages of the disease. Due to the multiple organ involvements in the acute phase, it is conceivable that - in a significant proportion of patients - longterm sequels in various organ systems might occur, thereby impacting the individual's health status and quality of life; and posing a relevant burden to the resources of the health care system\n\nAssessment of SARS-CoV-2-longterm morbidity and sequels on the population level:\n\nIn order to identify and treat these sequels in a timely fashion and to get a sense of the prevalence of such SARS-CoV-2 sequels on the population level, it is important to collect follow-up data and to comprehensively re-examine a population-representative sample of SARS-CoV-2 infected individuals.\n\nWithin the COVIDOM study we will conduct deep clinical and biochemical phenotyping in population-representative samples in Germany. This will allow novel insights into disease pathogenesis and chronicity of virus infections.",[133],"COVID-19",[135,133,136,137,138,139,140,141,142,143,144],"SARS-CoV-2","COVID","Corona","longterm morbidity","Quality of Life","longterm consequences","Chronic impairment","Chronic dysfunction","Chronicity","Sequels","2020-12-18",{"date":147,"type":148},"2020-12-22","ACTUAL",{"date":150,"type":148},"2020-11-16",{"date":152,"type":129},"2030-12-31",{"name":5,"class":6},3]